J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Ultrasound Clinical Account Specialist - Cardiac Sonographer, Electrophysiology

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Nashville, TN, USA+1 moreMore locations: Montgomery, AL, USA
In PersonField-based role; travel up to 40% overnight locally, regionally, and nationally, sometimes on short notice.
Solution EngineeringImplementation & Technical Account Management

About the job

Requirements
  • A bachelor's degree or four years of relevant professional work or military experience is required.
  • At least two years of experience in a clinical echocardiography laboratory is required.
  • Candidates must hold and maintain Registered Cardiac Sonographer (RCS) or Registered Diagnostic Cardiac Sonographer (RDCS) certification in adult or pediatric echocardiography.
  • Candidates must maintain advanced clinical ultrasound and echocardiography knowledge, including technology, advancements, and the business landscape.
  • Candidates must maintain clinical knowledge of the healthcare industry, disease states, and therapeutic and institutional trends.
  • A valid driver's license issued in the United States is required.
  • Candidates must maintain advanced clinical knowledge of cardiac ablation and cardiac imaging, and technical knowledge of electrophysiology technology, advancements, and the business landscape.
  • Candidates must be willing and able to travel up to 40% overnight locally, regionally, and nationally, sometimes on short notice.
  • The position requires sitting for extended periods, working in a hospital laboratory setting, attending live patient cases, wearing protective gear such as lead aprons, and working variable hours to meet patient needs.
  • Candidates may be required to lift up to 60 pounds.
Responsibilities
  • Provide expert clinical product and technical assistance and training to electrophysiology and interventional cardiology physicians and staff on effective use of AcuNav and SOUNDSTAR catheters in electrophysiology and interventional cardiology procedures.
  • Provide expert clinical product and technical assistance and training to physicians and electrophysiology laboratory staff on effective use of electrophysiology systems and catheter equipment, including the CARTO System, CARTOSOUND and CARTOMERGE software modules, and the Stockert RF generator, during case procedures within the assigned geography and in support of business goals.
  • Educate customers on electrophysiology products by providing technical and clinical information and in-service training, and share best practices to increase customer value.
  • Use consultative selling techniques to identify potential sales opportunities within accounts.
  • Create awareness of electrophysiology solutions and facilitate Territory Sales Manager contact with key decision-makers to drive incremental business.
  • Maximize customer case-support capability through effective planning and scheduling.
  • Collaborate and maintain consistent, open communication with internal partners, including regional teams, Territory Managers, electrophysiology Clinical Account Specialists, other Ultrasound Clinical Account Specialists, Marketing, Field Service Engineers, and Regional Business Directors.
  • Collaborate and maintain consistent, open communication with external partners.
  • Develop and share best practices with U.S. Field Sales and Service colleagues and internal partners, and develop mutually beneficial customer relationships within and beyond electrophysiology and interventional cardiology laboratories, including physicians, nurses, technicians, clinical and hospital administrators, and staff.
  • Stay current on company product instructions for use, best practices, technical troubleshooting, relevant scientific clinical literature, and new product information.
  • Prioritize and respond appropriately to requests in a high-stress environment while maintaining composure and a problem-solving focus during stressful interactions.
  • Engage in diagnostic dialogue with internal and external business partners and stakeholders and formulate solutions based on the dialogue and input gathered.
  • Mentor new electrophysiology commercial team members as requested.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience in an electrophysiology or catheterization laboratory, or in the electrophysiology or cardiovascular device industry.
  • At least one of the following industry certifications: CEPS (IBHRE), RCES, or RCIS.
  • Experience working with highly complex technical systems or in a critical patient-care setting.
  • Ability to communicate effectively and promptly with coworkers and all levels of the patient-care team.
  • Ability to work independently in a dynamic environment and adapt to changing conditions.
  • Ability to solve problems and think critically in high-pressure environments.
  • Ability to receive constructive feedback and collaborate effectively in a team environment.
  • Ability to translate large amounts of data into actionable insights.
  • Interest in learning and building new skills.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.